Cost-effectiveness of dabigatran for stroke prevention in atrial fibrillation in Switzerland

Cost-effectiveness of dabigatran for stroke prevention in atrial fibrillation in Switzerland

OBJECTIVES: Atrial fibrillation is a major risk factor for ischemic stroke and anticoagulation therapy is indicated to reduce risk. Dabigatran is a new oral anticoagulant that does not require INR monitoring. This study evaluated the cost-effectiveness of dabigatran versus vitamin K antagonist...

Full description

Bibliographic Details
Main Authors: Mark Pletscher, Rafael Plessow, Klaus Eichler, Simon Wieser
Format: Article
Language:English
Published: SMW supporting association (Trägerverein Swiss Medical Weekly SMW) 2012-12-01
Series:Swiss Medical Weekly
Subjects:
atrial fibrillation
Cost-effectiveness
dabigatran
direct thrombin inhibitor
ICER
ischemic stroke
Online Access:https://www.smw.ch/index.php/smw/article/view/1805

Similar Items

Similar Items